Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 17th year with 6,700-plus investor and partner meetings, facilitated by in-person and online connections. In addition, more than 340 company presentations and 28 panels helped shape the 2025 biotechnology outlook for attendees.
New programming this year included the TechBio Showcase, which explored the innovations and trends shaping biotech. Other discussions spanned a broad range of topics, including advancements in cell and gene therapy, enhancing longevity, collaboration opportunities in the Asia Pacific region, trends in biotech, financing, investment and business development partnerships.
“The quality of both the speakers and company presentations at this year’s Biotech Showcase conference was absolutely outstanding,” said Anna Chrisman, global managing director, EBD Group, in a press release.
More than 100 speakers shared their expertise and varying perspectives, including: Grace Colón, CEO & Co-Founder, Inaya Therapeutics, BIO Executive Committee Member; Olga Danilchanka, Partner, MRL Ventures Fund, Merck; Alessandro Falcone, Head, JLABS Singapore, Johnson & Johnson; and James Healy, Managing Partner, Sofinnova Investments, among others representing executives from large to mid-sized pharma, biotech, associations and investment firms.
For more articles from EBD Events or the partnering and investment landscape, visit our sister media site.
Photo: Depositphotos@